PT Inquest is an online journal club. Hosted by Jason Tuori, Megan Graham, and Chris Juneau, the show looks at an article every week and discusses how it applies to current physical therapy practice.
…
continue reading
محتوای ارائه شده توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Player FM - برنامه پادکست
با برنامه Player FM !
با برنامه Player FM !
Prof. John G. Gribben, MD, DSc - Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking Treatment
Manage episode 353711917 series 41876
محتوای ارائه شده توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Go online to PeerView.com/NMB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current chronic lymphocytic leukemia (CLL) management tool kit is expanding to include covalent and non-covalent BTK inhibitors, BCL-2 inhibitors, chemo-sparing combinations, and cellular therapies—are you prepared for this challenging and exciting new era in care? This “Seminars & Tumor Board” activity, adapted from our recent live event preceding the 64th ASH Annual Meeting and Exposition, can prepare you to adapt your practice through expert-led, case-based discussion with mini seminars designed to illustrate how fully integrating cutting-edge treatments can improve care in different and often challenging treatment settings. This program also features important resources from our collaborative partner, the CLL Society, that can be used to engage with your CLL patients during disease management. Upon completion of this activity, participants should be better able to: Cite the current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines supporting the use of targeted and other novel therapies in CLL, including safety, efficacy, and selectivity differences; Select personalized frontline regimens with targeted therapies as single agents or as part of combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations; Develop appropriate sequential and combinatorial treatment plans with targeted agents and cellular therapies for patients with therapeutic intolerance and/or R/R CLL; and Manage unique safety considerations associated with the use of targeted agents or other novel therapies in the CLL setting.
…
continue reading
588 قسمت
Manage episode 353711917 series 41876
محتوای ارائه شده توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Go online to PeerView.com/NMB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current chronic lymphocytic leukemia (CLL) management tool kit is expanding to include covalent and non-covalent BTK inhibitors, BCL-2 inhibitors, chemo-sparing combinations, and cellular therapies—are you prepared for this challenging and exciting new era in care? This “Seminars & Tumor Board” activity, adapted from our recent live event preceding the 64th ASH Annual Meeting and Exposition, can prepare you to adapt your practice through expert-led, case-based discussion with mini seminars designed to illustrate how fully integrating cutting-edge treatments can improve care in different and often challenging treatment settings. This program also features important resources from our collaborative partner, the CLL Society, that can be used to engage with your CLL patients during disease management. Upon completion of this activity, participants should be better able to: Cite the current evidence from pivotal clinical trials, head-to-head comparisons, and practice guidelines supporting the use of targeted and other novel therapies in CLL, including safety, efficacy, and selectivity differences; Select personalized frontline regimens with targeted therapies as single agents or as part of combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations; Develop appropriate sequential and combinatorial treatment plans with targeted agents and cellular therapies for patients with therapeutic intolerance and/or R/R CLL; and Manage unique safety considerations associated with the use of targeted agents or other novel therapies in the CLL setting.
…
continue reading
588 قسمت
همه قسمت ها
×به Player FM خوش آمدید!
Player FM در سراسر وب را برای یافتن پادکست های با کیفیت اسکن می کند تا همین الان لذت ببرید. این بهترین برنامه ی پادکست است که در اندروید، آیفون و وب کار می کند. ثبت نام کنید تا اشتراک های شما در بین دستگاه های مختلف همگام سازی شود.